Avexa Says No Evidence of Resistance to HIV Drug After 96 Weeks

Biotechnology company Avexa Ltd. reported positive data on its ongoing Phase IIb clinical trial of apricitabine, or ATC, stating that there was no signature resistance to ATC after 96 weeks of treatment, with over 85% of patients’ HIV levels below detectable.
RTTNews